Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hiroaki Wakimoto, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Hiroaki Wakimoto and William Curry.
Connection Strength

1.740
  1. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020 08 20; 9(1):1806662.
    View in: PubMed
    Score: 0.232
  2. Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358.
    View in: PubMed
    Score: 0.189
  3. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65.
    View in: PubMed
    Score: 0.172
  4. Targeting Hypoxia-Inducible Factor 1a in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol. 2015 Jul; 74(7):710-22.
    View in: PubMed
    Score: 0.163
  5. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909.
    View in: PubMed
    Score: 0.149
  6. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep; 71(3):741-8; discussion 748.
    View in: PubMed
    Score: 0.134
  7. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb; 14(2):132-44.
    View in: PubMed
    Score: 0.126
  8. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.
    View in: PubMed
    Score: 0.106
  9. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.057
  10. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058.
    View in: PubMed
    Score: 0.054
  11. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21.
    View in: PubMed
    Score: 0.054
  12. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
    View in: PubMed
    Score: 0.053
  13. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
    View in: PubMed
    Score: 0.050
  14. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 03 31; 355(6332).
    View in: PubMed
    Score: 0.046
  15. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784.
    View in: PubMed
    Score: 0.042
  16. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
    View in: PubMed
    Score: 0.038
  17. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20; 344(6190):1396-401.
    View in: PubMed
    Score: 0.038
  18. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24; 157(3):580-94.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.